ArTificial inTelligence-based RAdiogenomics in Colon Tumors

Launched by UNIVERSITY OF ROMA LA SAPIENZA · Oct 24, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "ArTificial inTelligence-based RAdiogenomics in Colon Tumors," is studying how artificial intelligence (AI) can help understand colon tumors in patients with stage II and III colon cancer. The main goal is to see if an AI model, which looks at imaging features from CT scans along with other health information, can identify how aggressive a tumor is and predict how it might behave in the future. This could help doctors make better treatment decisions.

To participate in this trial, you need to have been diagnosed with stage II or III colon cancer, and you must have a specific type of CT scan taken when your cancer was diagnosed. If you join the study, you'll have a CT scan before your surgery to remove the cancer, and if needed, you may receive additional treatment afterward following current medical guidelines. The trial is currently looking for participants aged between 65 and 74, and it welcomes individuals of all genders. Remember, to be eligible, you must have the right type of CT images available, so it's important to check that before considering participation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with pathologically proven stage II and stage III colon cancer;
• • availability of a CT scan with portal-venous phase at the time of diagnosis;
• • availability of immunohistochemical panel
• Exclusion Criteria:
• • patients with no CT images prior to surgical resection;
• • patients with CT scans characterized by motion artifacts preventing radiomics analysis